ライフサイエンスコーパス: TDM

1 TDM compromises the host response to mycobacterial speci

2 TDM data for infliximab or adalimumab was obtained.

3 TDM downregulated MHC class II cell surface expression a

4 TDM episodes were 24.9% by volume, but generated signifi

5 TDM measurements were determined by commercial ELISA (LI

6 TDM of asparaginase results in a significant reduction o

7 TDM was obtained in 30.7% (28.8% UC, 31.4% CD; P = 0.72)

8 TDM was performed in 40.1% of patients (43.5% UC, 38.0%

9 TDM was performed, and measurements were compared to typ

10 TDM-guided dosing improved clinical and microbiological

11 TDM-guided dosing was associated with improved clinical

12 TDM-IPIV promotes a hypercoagulopathy state, independent

13 Analysis of 14 TDMs by methylation-specific PCR and by bisulfite genomi

14 onjunction with virtual RLGS to identify 150 TDMs.

15 One hundred twelve IBD patients (with 214 TDM measurements, CD/UC 84/28, male/female 50/62, mean a

16 . tuberculosis, suggesting the presence of a TDM-specific esterase in this pathogen.

17 ich an immobile hydrophobic layer supports a TDM-rich, two-dimensionally fluid leaflet.

18 Adalimumab TDM based on pragmatic serum sampling is clinically viab

19 In addition, TDM modification by the cyclopropane synthase pcaA was b

20 Clinical improvement after TDM-guided dose escalation occurred in 13 of 15 (87%) no

21 or to standard induction regimen, and CA and TDM maintenance strategies were similarly efficacious.

22 s that the mechanisms responsible for DM and TDM formation might be closely related.

23 The results of DOS and TDM analysis further corroborated these findings.

24 nsfer (ICT) was demonstrated via the DOS and TDM graphical maps.

25 analysis which further supported by DOS and TDM.

26 Mice that received TDM-IV and TDM-IPIV had inflammatory pathologic findings with incre

27 irulence-associated lipids such as PDIMs and TDM.

28 crophages were equally responsive to TDB and TDM.

29 erformed TDM on HBase by up to 351 times and TDM on MySQL Cluster by up to 9 times.

30 Further, DOS pictographs and TDMs heat maps also supported FMO results, corroborating

31 f serum drug levels and antidrug antibodies (TDM group; n = 207) or standard infliximab therapy witho

32 f serum drug levels and antidrug antibodies (TDM group; n = 228) or to standard infliximab therapy wi

33 nform clinical decision making when applying TDM in a reactive setting.

34 icate that 5% or more of the CpG islands are TDMs, disputing the general notion that all CpG islands

35 macrophage transcriptome by IFN-gamma and by TDM or its synthetic analogue trehalose-6,6-dibehenate (

36 s1 relieved inhibition of GBP1 expression by TDM.

37 Transcriptional programs induced by TDM and TDB were highly similar but clearly distinct fro

38 ic DNA-containing Double Minute chromosomes (TDMs).

39 In contrast, TDM/TDB exerted delayed inhibition of IFN-gamma-induced

40 mab concentrations and/or clinical criteria (TDM; n = 92); exploratory end points were evaluated at w

41 ociated with daptomycin exposure, daptomycin TDM and model-informed precision dosing may help optimiz

42 Specifically, previously determined TDM electric fields exerted onto nitrile-containing o-cy

43 Anti-trehalose 6,6'-dimycolate (TDM) IgG responses were the strongest predictor for diff

44 Trehalose 6,6'-dimycolate (TDM) is a cell wall glycolipid and an important virulenc

45 Trehalose 6,6'-dimycolate (TDM) is the most abundant, most granulomagenic, and most

46 ia recognition of trehalose-6,6'-dimycolate (TDM), has opened avenues for the rational design of such

47 l cording factor, trehalose 6,6'-dimycolate (TDM), is a physiologically relevant and useful molecule

48 ll wall component trehalose-6,6'-dimycolate (TDM).

49 ll wall component trehalose 6,6'-dimycolate (TDM).

50 ycolipids such as trehalose 6,6'-dimycolate (TDM; cord factor).

51 Trehalose 6'6-dimycolate (TDM) activates innate inflammation and likely also stimu

52 terial cord factor trehalose-6,6-dimycolate (TDM) binds the C-type lectin receptor MINCLE and induces

53 terial cord factor trehalose-6,6-dimycolate (TDM), is a potent adjuvant inducing strong Th1 and Th17

54 Trehalose-6,6-dimycolate (TDM), the mycobacterial cord factor, and its synthetic a

55 Trehalose-6,6-dimycolate (TDM), the mycobacterial cord factor, is an abundant cell

56 c acid (MA)-containing trehalose dimycolate (TDM) and mycolyl arabinogalactan peptidoglycan (mAGP), i

57 ll envelope glycolipid trehalose dimycolate (TDM) is critical for Mtb growth during the first week of

58 f the mycolic acids on trehalose dimycolate (TDM) mediated by proximal cyclopropane synthase of alpha

59 olic acids attached to trehalose dimycolate (TDM) on the murine immune response to infection (see the

60 onomycolate (TMM), and trehalose dimycolate (TDM), important constituents of the outermost layer of t

61 M is newly synthesized trehalose dimycolate (TDM), which is cleaved by a novel TDM-specific serine es

62 envelope glycolipid is trehalose dimycolate (TDM).

63 sors of MA-containing trehalose dimycolates (TDM) and mycolyl arabinogalactan peptidoglycan, but the

64 n evaluating the implications of the drought TDM.

65 ame, tandem duplication of exons 2 - 7 (EGFR.TDM/2 - 7).

66 High-affinity binding is reduced in EGFR.TDM/18-26, although the t1/2 of receptor internalization

67 however, phosphorylation of the 180-kDa EGFR.TDM/2 - 7 was strongly induced by ligand.

68 Compared with unreinforced embankments, TDM columns achieved superior performance, with settleme

69 demonstrate how this modification can enable TDM applications by quantitatively and dynamically measu

70 7.6% (95% CI, 9.0%-26.2%; P < .001) favoring TDM.

71 A-BLIP sensors provide a rapid biosensor for TDM of trastuzumab and ipilimumab with the potential to

72 use developed software package developed for TDM of mAbs.

73 Finally, we propose a stepwise flowchart for TDM of DOX and present our perspective at curtailing thi

74 The challenge, however, is that FTIR for TDM is limited by the strong mid-IR absorption of endoge

75 (1.67 m) reduced settlements to 0.0032 m for TDM compared with 0.023 m at wider spacing (3.0 m).

76 l as a highly specific, modular solution for TDM.

77 and the developed assay systems suitable for TDM purposes.

78 These designed substrates were utilized for TDM of paclitaxel and cyclophosphamide in blood serum.

79 n 85A more efficiently mycolates TMM to form TDM, whereas C (and to a lesser extent B) has a higher r

80 of i.v. TDM in oil/water emulsion was given (TDM-IV).

81 23.4 weeks) and in all nonresponders who had TDM-guided switch in biologic due to supratherapeutic dr

82 The ratio of horizontal TDMs of the perovskite nanoplatelet film is ~84%, which

83 However, TDM is useful in several situations, such as pregnancy,

84 ption of the development of immunoanalytical TDM systems for LNZ.

85 d trough concentrations commonly utilized in TDM are not strong predictors of the detrimental clinica

86 The responses to TDM-IP, TDM-IV, or TDM-IPIV were consistent between mouse strain

87 to better assess the utility of beta-lactam TDM in critically ill patients.

88 current evidence is insufficient to mandate TDM in routine practice, a concerted investigation shoul

89 c polymorphisms (transcript derived markers, TDMs) from an experiment involving two commercial variet

90 Two-dimensional materials (TDMs) including graphene and its derivatives, transition

91 of states (DOS), transition density matrix (TDM), binding energy (E(b)), open circuit voltage (V(oc)

92 of states (DOS), transition density matrix (TDM), binding energy (E(b)), UV-Visible (UV-Vis), natura

93 orbitals (FMOs), transition density matrix (TDM), natural bond orbitals (NBOs), density of states (D

94 tage (V(oc)), and transition density matrix (TDMs) were performed to examine the optical, photophysic

95 sorption spectra, transition density matrix (TDMs), density of states (DOS), natural bond orbital (NB

96 ontent in stover and seed, total dry matter (TDM) in different growth stages, leaf area index (LAI),

97 The Granier-type thermal-dissipation method (TDM) is the most widely used sap-flow technique.

98 on HBase to the traditional SQL data model (TDM) implemented on both HBase and MySQL Cluster, using

99 velopment of a tolerance distribution model (TDM), a novel quantitative tool to assess landscape leve

100 pholipid mixtures with as little as 25 mol % TDM.

101 ientation of their transition dipole moment (TDM) are two emerging strategies to enhance the efficien

102 While optical transition dipole moments (TDMs) in zero to two-dimensional optical emitters have b

103 ios of horizontal transition dipole moments (TDMs) is expected to boost the photon outcoupling of pla

104 Therapeutic drug monitoring (TDM) aid therapeutic decision making in patients with in

105 may be used for therapeutic drug monitoring (TDM) as MTX-PG is thought to mediate MTX's efficacy.

106 ftware based on therapeutic drug monitoring (TDM) data.

107 availability of therapeutic drug monitoring (TDM) for ampicillin and ceftobiprole has prompted the us

108 Therapeutic drug monitoring (TDM) for biologic therapies in inflammatory bowel diseas

109 DBS method for therapeutic drug monitoring (TDM) for improving the efficacy and safety of drug thera

110 Proactive therapeutic drug monitoring (TDM) has been proposed to improve outcomes in patients w

111 Therapeutic drug monitoring (TDM) has emerged as a strategy for treatment optimizatio

112 does proactive therapeutic drug monitoring (TDM) improve outcomes as compared with standard care?

113 s available for therapeutic drug monitoring (TDM) in cancer patients treated with DOX.

114 e importance of therapeutic drug monitoring (TDM) in this population is also explored in this review.

115 Therapeutic drug monitoring (TDM) involves measuring drug levels in the patient blood

116 isation through therapeutic drug monitoring (TDM) is a key strategy in tackling antimicrobial resista

117 range to which therapeutic drug monitoring (TDM) is applied.

118 n such a trend, therapeutic drug monitoring (TDM) is especially crucial for patients with peritonitis

119 Therapeutic drug monitoring (TDM) is increasingly valuable for tailoring personalized

120 Routine therapeutic drug monitoring (TDM) is necessary to facilitate Tac management and to av

121 nt response but therapeutic drug monitoring (TDM) is yet to be implemented in routine psoriasis care.

122 djusted (CA) vs therapeutic drug monitoring (TDM) maintenance strategies in patients with moderately

123 Therapeutic drug monitoring (TDM) of antiepileptic drugs (AEDs) is widely established

124 e reported that therapeutic drug monitoring (TDM) of asparaginase (ASP) activity levels in plasma may

125 Therapeutic drug monitoring (TDM) of beta-lactam antibiotics is recommended to addres

126 ed as requiring therapeutic drug monitoring (TDM) or non-TDM.

127 nt and reactive therapeutic drug monitoring (TDM) prior to changes in biologic therapy.

128 Therapeutic drug monitoring (TDM) provides valuable guidance for dose adjustment of a

129 are needed for therapeutic drug monitoring (TDM) purposes in this context.

130 tients requires therapeutic drug monitoring (TDM) to ensure optimal therapy.

131 requires close therapeutic drug monitoring (TDM) to optimise dosage for individual patients.

132 ms that perform therapeutic drug monitoring (TDM) without relying on mAb specific reagents will be ne

133 d on vancomycin therapeutic drug monitoring (TDM), clinicians should recognize that the majority of v

134 Proactive therapeutic drug monitoring (TDM), consisting of individualized treatment based on sc

135 Proactive therapeutic drug monitoring (TDM), defined as individualized drug dosing based on sch

136 Therapeutic drug monitoring (TDM), genotype guided dosing, and chronomodulation have

137 vative tool for therapeutic-drug monitoring (TDM), making it an ideal candidate for personalized trea

138 Therapeutic drug monitoring (TDM), which involves measurement of drug or active metab

139 Therapeutic drug monitoring (TDM), which involves measuring drug levels in patients'

140 s and underwent therapeutic drug monitoring (TDM)-guided BL dosing adjustment within the first 72 hou

141 aboratories for therapeutic drug monitoring (TDM).

142 vidualized with therapeutic drug monitoring (TDM).

143 care method for therapeutic drug monitoring (TDM).

144 l candidate for therapeutic drug monitoring (TDM).

145 A tetramer dimer monomer (TDM) equilibrium model is proposed to account for concen

146 The 180-kDa, tandem duplication mutant (TDM) exhibited enhanced basal phosphorylation and impair

147 escribe a 185-kDa tandem duplication mutant (TDM) that is expressed in KE and A-1235 glioma cells, al

148 We introduce a new TDM model that promotes inflammatory lung pathologic fin

149 ing therapeutic drug monitoring (TDM) or non-TDM.

150 e EHR encounters and workload hours than non-TDM episodes.

151 specifically binds both TMM and PE, but not TDM, in the micromolar range.

152 imycolate (TDM), which is cleaved by a novel TDM-specific serine esterase, Msmeg_1529.

153 duced in lung tissue after administration of TDM to mice.

154 c studies, and focused on the application of TDM for biologic therapy, specifically anti-tumor necros

155 Our aim is to assess the benefit of TDM of newer generation AEDs in epilepsy.

156 rcolation, implying that the connectivity of TDM plays a crucial role in membrane preservation.

157 sh cmaA2-dependent trans-cyclopropanation of TDM as a suppressor of M. tuberculosis-induced inflammat

158 The efficacy of TDM and its effect on asparaginase-associated toxicity a

159 advances have been achieved in the field of TDM-based PSCs.

160 Furthermore, enzymatic hydrolysis of TDM remains conserved in M. tuberculosis, suggesting the

161 However, the impact of TDM on IFN-gamma-induced macrophage activation is not kn

162 However, the impact of TDM-guided dosing on clinical outcomes remains unknown.

163 ivation through cyclopropane modification of TDM as a critical pathogenic strategy of Mtb.

164 ta, this review does not address the role of TDM for more recently approved biologic agents, such as

165 In order to study the role of TDM in the innate immune response to Mycobacterium tuber

166 ioritized clinical guidelines on the role of TDM in the management of inflammatory bowel disease.

167 d showed agonist activity similar to that of TDM, despite their much simpler structure.

168 inical activity were recorded at the time of TDM.

169 until it is able to activate the toxicity of TDM and initiate necrosis that results in caseating gran

170 was caused by activation of the toxicity of TDM toxicity.

171 mab therapy and support the selective use of TDM in IBD patients treated with adalimumab.

172 of treatment, highlighting the usefulness of TDM in clinical practice.

173 ogress in the development and application of TDMs (i.e., graphene, graphdiyne, transition metal dicha

174 estimates about the number and direction of TDMs in FlH(-), as well the electronic structure changes

175 The effect of TDMs and 2D perovskites on the charge carrier dynamics o

176 study the dimensionality and orientation of TDMs in CdSe quantum rings.

177 multaneously controlling the orientations of TDMs, achieving high photoluminescence quantum yields (P

178 With this set of TDMs, we constructed a genetic map and used it for the g

179 ith 10 mug of i.p. TDM in light mineral oil (TDM-IP).

180 ery of membrane mobility upon rehydration on TDM fraction shows a functional form indicative of spati

181 This review provides an update on TDM with biologic and oral small molecules, evaluates th

182 In defined medium, both oncogenic TDM are constitutively autophosphorylated and inefficien

183 Injections of MTB and/or TDM into sensitized mice induced caseating granulomas th

184 one objective disease activity assessment or TDM in the 12 weeks prior (CD 67.9%, UC 66.2%; P = 0.79)

185 % patients underwent objective assessment or TDM prior.

186 rgo objective disease activity assessment or TDM.

187 The responses to TDM-IP, TDM-IV, or TDM-IPIV were consistent between mouse strains.

188 e and cytokine release in response to TDB or TDM.

189 knockdown caused on average reduced TDB- or TDM-induced IL-8 production.

190 d reduced phagocytosis of M. tuberculosis or TDM-coated latex beads.

191 olymorphism case, CGDM on HBase outperformed TDM on HBase by up to 351 times and TDM on MySQL Cluster

192 ALB/c mice were injected with 10 mug of i.p. TDM in light mineral oil (TDM-IP).

193 ed with mice injected once with i.v. or i.p. TDM.

194 In particular, TDM represents a useful tool to discriminate poor adhere

195 spectrometry (LC-MS) can be used to perform TDM of mAbs in the same manner as smaller nonbiologic dr

196 ng, enhances the feasibility of personalized TDM, supporting tailored treatment strategies that can i

197 of pathology in lungs of mice at 7 days post-TDM introduction.

198 hey have side effects that require a precise TDM to try to minimize them.

199 Proactive TDM led to dose reduction in five individuals with clear

200 Proactive TDM of intravenous infliximab during maintenance treatme

201 A weak recommendation against proactive TDM for adalimumab and other biologic drugs during maint

202 A weak recommendation against proactive TDM for intravenous infliximab, adalimumab, and other bi

203 ther research is needed to compare proactive TDM with reactive TDM, to assess the effects on long-ter

204 e trial evidence was available for proactive TDM of adalimumab at induction (start) of treatment.

205 e trial evidence was available for proactive TDM of other biologic drugs in maintenance or at inducti

206 adalimumab, it remains unclear if proactive TDM during maintenance treatment has an effect on sustai

207 of laboratory assays to implement proactive TDM should also be considered.

208 In proactive TDM, serum drug levels and anti-drug antibodies are meas

209 intenance therapy with infliximab, proactive TDM was more effective than treatment without TDM in sus

210 A weak recommendation in favour of proactive TDM for intravenous infliximab during maintenance treatm

211 The role of proactive TDM in clinical practice remains unclear, with conflicti

212 best current research evidence on proactive TDM did not suggest heterogeneity of effects on outcomes

213 nts were randomized 1:1 to receive proactive TDM with dose and interval adjustments based on schedule

214 and risks of a strategy of routine proactive TDM (during routine clinical care in patients with quies

215 Routine proactive TDM to target biologic concentration to specific thresho

216 Patients in the proactive TDM arm were more likely to undergo dose escalation (RR,

217 Patients were randomized 1:1 to proactive TDM with dose and interval adjustments based on schedule

218 At induction (start) of treatment, proactive TDM of intravenous infliximab may have little or no effe

219 emission in patients who underwent proactive TDM (267/709; 38%) vs conventional management (292/696;

220 evaluates the role of reactive vs proactive TDM, and identifies the gaps in current evidence.

221 owever, it remains unclear whether proactive TDM improves clinical outcomes during maintenance therap

222 However, whether proactive TDM improves clinical outcomes when implemented at the t

223 Purified TDM isolated from a cyclopropane-deficient pcaA mutant w

224 Finally, purified TDM lacking trans-cyclopropane rings was 5-fold more pot

225 Noninfectious models using purified TDM oil/water emulsions elicit pathologic findings obser

226 jor role in R-TDR, and it is essential for R-TDM.

227 chanism of RNA-templated DNA modification (R-TDM) induced by spontaneous or mutagen-induced breaks.

228 promising solution for decentralised, rapid TDM in clinical settings, especially where timely dose o

229 benefits and risks of a strategy of reactive TDM (in patients with active inflammatory bowel disease)

230 eeded to compare proactive TDM with reactive TDM, to assess the effects on long-term disease complica

231 individuals treated with adalimumab received TDM.

232 Mice that received TDM-IV and TDM-IPIV had inflammatory pathologic findings

233 -specific differentially methylated regions (TDMs) were first identified, and then expression of gene

234 e at each appointment, whereas in the rescue TDM arm, levels were known only if a study endpoint was

235 58% in the systematic, and 53% in the rescue TDM arm, p = 0.6, Cox regression).

236 olled trial comparing systematic with rescue TDM of lamotrigine, levetiracetam, oxcarbazepine, topira

237 quiescent disease) compared with no routine TDM.

238 the absorption transition dipole moment(s) (TDMs) in the molecular frame of reference.

239 ng an anticancer drug (doxorubicin), several TDM-requiring antidepressant and anti-seizure drugs, fru

240 oped in adipose tissue, but MTB with surface TDM removed induced only acute inflammation that did not

241 In the systematic TDM arm, AED plasma levels were available at each appoin

242 ype lectin receptors Mincle and Mcl bind TDB/TDM and activate macrophages and dendritic cells (DC) th

243 ulation of Mincle, resulting in enhanced TDB/TDM-induced kinase activation and more rapid inflammator

244 However, TDB/TDM-triggered kinase activation has not been studied wel

245 SYK-CARD9 signaling plays a key role in TDB/TDM-induced activation of innate immune cells in man as

246 eta showed nearly complete abrogation of TDB/TDM responsiveness, but also failed to upregulate Mincle

247 We performed in vitro analysis of TDB/TDM-stimulated primary human monocytes, macrophages, and

248 In this article, we report that TDB/TDM caused only weak Syk-phosphorylation in resting macr

249 tically, the transcriptional response to TDB/TDM has been defined to require FcRgamma-Syk-Card9 signa

250 To dissect transcriptional responses to TDB/TDM, we mined microarray data and identified early growt

251 s sufficient to confer responsiveness to TDB/TDM.

252 e requirement for Mcl in the response to TDB/TDM.

253 The i.p./i.v. TDM (TDM-IVIP) group was compared with mice injected once wit

254 HBase performed up to 246 times faster than TDM on HBase and 7 times faster than TDM on MySQL Cluste

255 er than TDM on HBase and 7 times faster than TDM on MySQL Cluster.

256 This new model argues that TDM is sufficient to generate the hypercoagulopathy obse

257 We have found that TDM monolayers, in stark contrast to phospholipid membra

258 We found that TDM-coated beads induced MMP-9 expression and activity i

259 ng, and other stresses, we hypothesized that TDM alone may suffice to confer dehydration resistance t

260 The findings indicate that TDM columns provide superior seismic performance through

261 Here, it is shown that TDM is a major driver of the early M1-like macrophage re

262 rculous granulomas, our results suggest that TDM may drive MMP expression during TB pathogenesis.

263 These findings suggest that TDM plays a role in establishment of the M1-like shift i

264 o-dimensional optical emitters, we find that TDMs in CdSe quantum rings show a peculiar in-plane line

265 We speculate that TDMs are formed through the recombination of telomeres w

266 The TDM and DOS calculations confirmed efficient charge tran

267 The TDM columns also demonstrated more controlled consolidat

268 The TDM is demonstrated by downscaling emissions from the el

269 The TDM-based MTBE demonstrated superior sensitivity compare

270 The TDM-IPIV group had increased CD4(+) T cells in lung tiss

271 n inflammatory and T-cell cytokines, and the TDM-IPIV group had further enhancement of IL-10 and gran

272 Raman activities of many analytes hinder the TDM application of SERS.

273 As a case study, we implement the TDM in the Virginia-Carolinas region and compare its res

274 Importantly, the TDM of the spin-coated film shows preferential horizonta

275 f 198 and 106 (53.0%) of 200 patients in the TDM and standard therapy groups, respectively (adjusted

276 patients (68%) and 139 patients (70%) in the TDM and standard therapy groups, respectively.

277 patients (60%) and 142 patients (63%) in the TDM and standard therapy groups, respectively.

278 was observed in 167 patients (73.6%) in the TDM group and 127 patients (55.9%) in the standard thera

279 .9] years; 209 women [51%]), 398 (198 in the TDM group and 200 in the standard therapy group) receive

280 contrast, AMOEBA robustly recapitulates the TDM electric fields.

281 Some of the TDMs are within 5' promoter CpG islands of genes, which

282 The directions of the TDMs in oxidized and semiquinone flavins were characteri

283 re up- or downregulated in response to these TDM-coated beads compared to control beads.

284 le of 17 climate change models to drive this TDM, we estimate that 18% of US ecosystems are vulnerabl

285 Thus, TDM-based MTBE can be potentially used as a screening de

286 Partial adherence of clinicians to TDM (adjusting or not AED dosage based on blood levels)

287 this protection from dehydration extends to TDM-phospholipid mixtures with as little as 25 mol % TDM

288 The responses to TDM-IP, TDM-IV, or TDM-IPIV were consistent between mous

289 oretical modeling reveals that this uniaxial TDM originates from broken rotational symmetry in the qu

290 lid samples from 500 patients and 817 unique TDM occasions were analyzed.

291 In the future, adaptations to how we use TDM may contribute further to the goal of personalized t

292 f loss of response (LOR) to adalimumab using TDM in IBD patients.

293 The i.p./i.v. TDM (TDM-IVIP) group was compared with mice injected onc

294 t day 7, another injection of 10 mug of i.v. TDM in oil/water emulsion was given (TDM-IV).

295 uld raise caution on contemporary vancomycin TDM recommendations.

296 The excessive vancomycin TDM for decades has been propagated with limitations in

297 The molecular mechanism by which TDM inhibits phagosome maturation has been elusive.

298 In addition, with TDM, silent inactivation and allergic-like reactions wer

299 iameter polystyrene microspheres coated with TDM.

300 CCL3, CCL4, and CCL2 after stimulation with TDM, whereas DC responded more strongly to TDB and GM-CS

301 DM was more effective than treatment without TDM in sustaining disease control without disease worsen